Anxiety
Articles about Anxiety
Tonix Pharmaceuticals Presented Data On TONMYATM In Treating Patients With Fibromyalgia At The 2026 AAPM Painconnect Annual Meeting
(MENAFN - GlobeNewsWire - Nasdaq) TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA ...
VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. ...
NEW YORK, March 07, 2026 (GLOBE NEWSWIRE) --
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business ...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‐of‐Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2...
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ...
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) investors of an upcoming deadline involving a securities fraud class action lawsuit...
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYATM and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years
VTGN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. ...
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) --
Psychologists are finding more ways to use virtual reality in therapy
From Rett and Pitt-Hopkins to ALS: 5 Rare Diseases UC San Diego Researchers are Tackling in the Lab
This Rare Disease Day (February 28, 2026), read on to learn more about five orphan conditions, the people they affect and the UC San Diego Sanford Stem Cell Institute researchers fanning the flames of hope for patients around the globe.
U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data --
As More Americans Embrace Anxiety Treatment, MAHA Derides Medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, claiming they’re harmful. Doctors and researchers say the MAHA movement is misrepresenting drugs that have been proved to safely treat chronic anxiety and point to broader social changes to explain their increased use.
As more Americans embrace anxiety treatment, RFK Jr. derides medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, but doctors and researchers say the MAHA movement is misrepresenting drugs that have been proven to help.
Contact The Gross Law Firm By March 16, 2026 Deadline To Join Class Action Against Vistagen Therapeutics, Inc.(VTGN)
(MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). ...